Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 04, 2023 07:00 ET | Source: Optinose, Inc.

Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE

The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis If...
October 21, 2022 07:00 ET | Source: Optinose, Inc.

Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022

Presentation highlights a greater than 60% reduction in acute exacerbations and need for antibiotics for chronic sinusitis patients who used XHANCE in landmark ReOpen phase 3 clinical trial program ...